2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.


Targeted Antibodies for Cancer 2011

Advertiment

Welcome to TAC 2011

In recent years, targeted antibodies have emerged as playing a pivotal role in cancer therapeutics and are an important area for the pharmaceutical, biotech and medical industries.

In such a fast-paced and competitive field, it is crucial for the key players to stay up-to date with the recent advances in antibody research and development.

TAC2011 will address the critical scientific issues and challenges associated with developing targeted therapeutic antibodies for cancer. It will highlight improvements in antibody development, global trends and current clinical progress.

Benefits of attending TAC 2011:

• Hear about the latest trends in antibody therapeutics for cancer: antibodies to watch in 2011 and the future
• Join in with the discussion about what biosimilars will mean for the pharma industry
• Understand the best strategies for improving antibody production
• Receive practical advice about taking antibodies from concept to reality with instructive case studies highlighting successful new antibodies in development
• Examine how to capture the potential of personalised antibody therapies for cancer
• Assess bispecific, trifunctional, radiolabelled antibodies and antibody-drug conjugates in the treatment of cancer
• Network with leading experts in the field and build up your business prospects

Who will you meet?

Participants at the conference will be vice-presidents, directors, CEOs, COOs, managers, heads, scientists and clinicians in:

oncology
antibody development and manufacture
protein engineering
personalised medicine
biomarker discovery
drug/medicine safety
licensing and patenting of drugs

Exhibition and sponsorship

TAC 2011 will provide you with a great opportunity to develop and increase your business prospects by networking with some of the leading experts and decision makers in the dynamic field of antibody research and development.

We would be delighted to help you market your services and products at this event through some of the great marketing packages that we have on offer.

Contact Michael Blackmore for more information on the packages available: +44(0) 20 7501 6746 michael.blackmore@markallengroup.com

Media partnerships and press information

Media Partnership:

TAC 2011 are delighted to invite press organisations, journals, newsletters and conference organisers to join us in a press partnership. We will help you advertise by:

Providing your company logo and a link to your website on our TAC 2011 website
Displaying your logo on promotional material that we will send out to the major pharmaceutical and biotech professionals throughout our 6 month promotional campaign
Displaying your promotional materials at TAC 2011

… in exchange for your help in promoting TAC 2011 on your website, in your journal/newsletter or at your conference

Press information

TAC 2011 are delighted to invite accredited members of the press to apply for a complimentary press pass. Press passes will be limited to those intending to report relevant events and news about the conference.

We require all published reports about TAC 2011 to be sent to the organisers.

For more information about media partnerships or press places, contact Flo Doel on +44 (0) 200 7501 6768 Flo.doel@markallengroup.com

Related Search

@netvision net il 2011 contacts,
Targeted Antibodies for Cancer 2011: 07.25.2011 · Posted in Cancer Conferences, Publications Tags: , ,

Leave a Reply

Suggested Posts

3rd World Circulating Tumor Cells Summit Welcome to TAC 2011 I rece t years, targeted a tibodies have emerged as playi g a pivotal role i ca cer therapeutics a d are a importa t area for the pharmaceutical, biotech a d medical i dustries. I such a fast-paced a d competitive field, it is crucial for the key players to stay up-to date with the rece t adva ces i a tibody [...]. Posted July 25th, 2011 | 3:47 am
Lilly’s Global Sourcing Strategy Model for Oncology Optimization Welcome to TAC 2011 I rece t years, targeted a tibodies have emerged as playi g a pivotal role i ca cer therapeutics a d are a importa t area for the pharmaceutical, biotech a d medical i dustries. I such a fast-paced a d competitive field, it is crucial for the key players to stay up-to date with the rece t adva ces i a tibody [...]. Posted July 25th, 2011 | 3:47 am
Chicago Live 2011: Endoscopic Advances in Gastrointestinal Malignancies Welcome to TAC 2011 I rece t years, targeted a tibodies have emerged as playi g a pivotal role i ca cer therapeutics a d are a importa t area for the pharmaceutical, biotech a d medical i dustries. I such a fast-paced a d competitive field, it is crucial for the key players to stay up-to date with the rece t adva ces i a tibody [...]. Posted July 25th, 2011 | 3:47 am
Spa Oncology Training Summit Welcome to TAC 2011 I rece t years, targeted a tibodies have emerged as playi g a pivotal role i ca cer therapeutics a d are a importa t area for the pharmaceutical, biotech a d medical i dustries. I such a fast-paced a d competitive field, it is crucial for the key players to stay up-to date with the rece t adva ces i a tibody [...]. Posted July 25th, 2011 | 3:47 am
Mouse Models of Cancer Welcome to TAC 2011 I rece t years, targeted a tibodies have emerged as playi g a pivotal role i ca cer therapeutics a d are a importa t area for the pharmaceutical, biotech a d medical i dustries. I such a fast-paced a d competitive field, it is crucial for the key players to stay up-to date with the rece t adva ces i a tibody [...]. Posted July 25th, 2011 | 3:47 am